At the San Antonio Breast Cancer Symposium, investigators presented results from HER2CLIMB-05, a registrational trial evaluating the addition of tucatinib (Tukysa) to trastuzumab (Herceptin) and ...

The Dallas Cowboys' offensive line is getting closer to a return to full strength ahead of the team's Week 6 showdown with the Carolina Panthers. This week, however, when the Cowboys make the trip to ...

He works in mysterious ways.

It can look different and feel different, but it is only different if, in fact, it actually is different. Soon enough, all the good, positive vibes mustered by the Giants about their offensive line ...

At the Stonewall National Monument in New York, where the Interior Department came under fire earlier this year for removing mentions of transgender people from the park’s website, visitors have left ...

We may receive a commission on purchases made from links. Every consumer battery that exists has little plus and minus signs on the outer labeling. These mark the ending and starting points for the ...

NEW YORK – Grail on Wednesday reported positive top-line performance and safety results from its Pathfinder 2 study, finding that adding its multi-cancer early detection (MCED) test to ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment significantly reduced the risk of progression or death in ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 study ...

In tough times, realistic optimism—not denial—is a leader’s best tool to inspire resilience, reduce fear, and guide teams through uncertainty. In the face of such pessimism, it's time for some ...

In the first phase 3 trial to show the superiority of a TROP2-targeted antibody-drug conjugate and an immunotherapy agent in first-line triple-negative breast cancer (TNBC), Gilead Sciences’ Trodelvy ...